SCAs guarantee ~$20B annual revenue against 25% capacity, with management targeting 50%; HBM is customized, not a commodity, and demand from auto/military is growing. If risk is indeed lower due to contracted revenue and zero debt, a 4% discount rate and 32x multiple are justified, implying current price is below fair value. The stock is at a technical bottom with v-shaped recovery, presenting a buying opportunity before HBM ramp and capacity locking. DCF assumptions are unrealistic (4% WACC, zero capex, permanent peak multiples); cyclical memory downturns historically crush margins; top commenter models a fair value of $680 using 10% discount rate.
SCAs guarantee ~$20B annual revenue against 25% capacity, with management targeting 50%; HBM is customized, not a commodity, and demand from auto/military is growing. If risk is indeed lower due to contracted revenue and zero debt, a 4% discount rate and 32x multiple are justified, implying current price is below fair value. The stock is at a technical bottom with v-shaped recovery, presenting a buying opportunity before HBM ramp and capacity locking. DCF assumptions are unrealistic (4% WACC, zero capex, permanent peak multiples); cyclical memory downturns historically crush margins; top commenter models a fair value of $680 using 10% discount rate.